Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 2, Février 2016
Page(s) 183 - 191
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163202012
Publié en ligne 2 mars 2016
  1. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013 ; 72 : 1747–1755. [CrossRef] [PubMed]
  2. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012 ; 51 : 1017–1026. [CrossRef] [PubMed]
  3. Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014 ; doi: 10.1136/annrheumdis-2014-206386.
  4. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013 ; 65 : 1953–1962. [CrossRef] [PubMed]
  5. Rabquer BJ, Hou Y, Del Galdo F, et al. The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatology (Oxford) 2009 ; 48 : 734–740. [CrossRef] [PubMed]
  6. Liu S, Parapuram SK, Leask A. Fibrosis caused by loss of PTEN expression in mouse fibroblasts is crucially dependent on CCN2. Arthritis Rheum 2013 ; 65 : 2940–2944. [CrossRef] [PubMed]
  7. Perros F, Humbert M, Cohen-Kaminsky S. Hypertension artérielle pulmonaire. Med Sci (Paris) 2013 ; 29 : 607–616. [CrossRef] [EDP Sciences] [PubMed]
  8. Ghatnekar A, Chrobak I, Reese C, et al. Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol 2013 ; 182 : 2391–2406. [CrossRef] [PubMed]
  9. Derrett-Smith EC, Dooley A, Gilbane AJ, et al. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013 ; 65 : 2928–2939. [CrossRef] [PubMed]
  10. Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014 ; 73 : 1880–1887. [CrossRef] [PubMed]
  11. Kuwana M, Okazaki Y. Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheum 2014 ; 66 : 1300–1305. [CrossRef]
  12. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum 2014 ; 66 : 714–725. [CrossRef]
  13. Takahashi T, Asano Y, Ichimura Y, et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheum 2015 ; 67 : 254–265. [CrossRef]
  14. Fuschiotti P, Larregina AT, Ho J, et al. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 2013 ; 65 : 236–246. [CrossRef] [PubMed]
  15. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011 ; 63 : 3575–3585. [CrossRef] [PubMed]
  16. Desallais L, Avouac J, Fréchet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014 ; 16 : R157. [CrossRef] [PubMed]
  17. Assassi S, Wu M, Tan FK, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013 ; 65 : 2917–2927. [CrossRef] [PubMed]
  18. Van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014 ; 370 : 433–443. [CrossRef] [PubMed]
  19. Arcand J, Robitaille G, Koenig M, et al. Heparin inhibits the interaction of DNA topoisomerase I/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts. Arthritis Rheum 2012 ; 64 : 1632–1641. [CrossRef] [PubMed]
  20. Moroncini G, Grieco A, Nacci G, et al. Epitope specificity determines pathogenicity and detectability of anti-PDGFRα autoantibodies in systemic sclerosis. Arthritis Rheum 2015 ; 67 : 1891–1903. [CrossRef]
  21. Günther J, Kill A, Becker MO, et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014 ; 16 : R65. [CrossRef] [PubMed]
  22. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014 ; 343 : 152–157. [CrossRef] [PubMed]
  23. Marangoni RG, Korman BD, Wei J, et al. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheum 2015 ; 67 : 1062–1073. [CrossRef]
  24. Palumbo-Zerr K, Zerr P, Distler A, et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 2015 ; 21 : 150–158. [CrossRef] [PubMed]
  25. Wei J, Zhu H, Komura K, et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis 2014 ; 73 : 446–454. [CrossRef] [PubMed]
  26. Distler A, Ziemer C, Beyer C, et al. Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis 2014 ; 73 : 624–627. [CrossRef] [PubMed]
  27. Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013 ; 503 : 126–130. [CrossRef] [PubMed]
  28. Dieudé P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011 ; 10 : 282–290. [CrossRef] [PubMed]
  29. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010 ; 42 : 426–429. [CrossRef] [PubMed]
  30. Allanore Y, Saad M, Dieudé P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011 ; 7 : e1002091. [CrossRef] [PubMed]
  31. Noda S, Asano Y, Nishimura S, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 2014 ; 5 : 5797. [CrossRef] [PubMed]
  32. Iwamoto N, Vettori S, Maurer B, et al. Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Ann Rheum Dis 2016 ; 75 : 303–310. [CrossRef] [PubMed]
  33. Wipff J, Allanore Y, Boileau C. Interactions entre la fibrilline-1 et le TGF-β. Med Sci (Paris) 2009 ; 25 : 161–167. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.